Initial medication purchase will last 10 weeks using our dosing escalation scale.

Tirzepatide, sold under the brand name Mounjaro, is a medication used for the treatment of type 2 diabetes. Tirzepatide is given by weekly subcutaneous injection.

Mounjaro, a drug approved in 2022 to treat type 2 diabetes, has also shown remarkable weight-loss effects, reducing trial participants’ weight by over 20%.

The most common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach (abdominal) pain. These are not all the possible side effects.

Do not use Terzepatide/Mounjaro if you or any of your family have ever had a type of thyroid cancer called MTC or if you have an endocrine system condition called MEN 2, or if you have had a serious allergic reaction to tirzepatide.